| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 51 | 2025 | 512 | 12.800 |
Why?
|
| Stomach Neoplasms | 67 | 2025 | 241 | 8.440 |
Why?
|
| Adenoma | 22 | 2021 | 96 | 6.720 |
Why?
|
| Colonic Polyps | 17 | 2021 | 71 | 6.550 |
Why?
|
| Crocus | 8 | 2024 | 21 | 4.550 |
Why?
|
| Helicobacter pylori | 28 | 2025 | 118 | 4.240 |
Why?
|
| Gastrointestinal Diseases | 6 | 2023 | 51 | 3.550 |
Why?
|
| Colonic Neoplasms | 14 | 2021 | 223 | 3.430 |
Why?
|
| Helicobacter Infections | 19 | 2025 | 86 | 3.300 |
Why?
|
| DNA Methylation | 17 | 2024 | 403 | 3.220 |
Why?
|
| Microsatellite Instability | 12 | 2024 | 48 | 3.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 41 | 2025 | 968 | 2.680 |
Why?
|
| Humans | 187 | 2026 | 43102 | 2.500 |
Why?
|
| Colonoscopy | 17 | 2025 | 122 | 2.490 |
Why?
|
| Adenocarcinoma | 14 | 2025 | 291 | 2.390 |
Why?
|
| Middle Aged | 73 | 2025 | 12222 | 2.140 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2024 | 104 | 1.980 |
Why?
|
| Male | 93 | 2025 | 23409 | 1.980 |
Why?
|
| Aged | 59 | 2025 | 8214 | 1.950 |
Why?
|
| Colitis | 3 | 2021 | 71 | 1.910 |
Why?
|
| Female | 90 | 2025 | 24698 | 1.760 |
Why?
|
| Liver Neoplasms | 4 | 2025 | 224 | 1.700 |
Why?
|
| Gastric Mucosa | 15 | 2025 | 65 | 1.570 |
Why?
|
| Carcinoma | 6 | 2024 | 108 | 1.490 |
Why?
|
| Risk Factors | 21 | 2025 | 3994 | 1.410 |
Why?
|
| Plant Extracts | 5 | 2024 | 302 | 1.380 |
Why?
|
| Retrospective Studies | 19 | 2025 | 2544 | 1.360 |
Why?
|
| Transcription Factors | 8 | 2025 | 735 | 1.350 |
Why?
|
| Adenomatous Polyps | 3 | 2016 | 13 | 1.340 |
Why?
|
| Precancerous Conditions | 5 | 2023 | 83 | 1.330 |
Why?
|
| Cell Line, Tumor | 55 | 2025 | 2676 | 1.320 |
Why?
|
| Promoter Regions, Genetic | 12 | 2020 | 526 | 1.310 |
Why?
|
| Mutation | 8 | 2023 | 1177 | 1.200 |
Why?
|
| Bacteria | 3 | 2021 | 293 | 1.190 |
Why?
|
| Hepatitis C, Chronic | 2 | 2020 | 44 | 1.130 |
Why?
|
| Adult | 44 | 2025 | 13872 | 1.120 |
Why?
|
| MicroRNAs | 12 | 2025 | 518 | 1.100 |
Why?
|
| Antigens, Bacterial | 12 | 2019 | 144 | 1.080 |
Why?
|
| Neoplasm Staging | 9 | 2025 | 374 | 1.060 |
Why?
|
| Apoptosis | 18 | 2022 | 1568 | 1.050 |
Why?
|
| Prevalence | 12 | 2025 | 1612 | 1.040 |
Why?
|
| Cell Proliferation | 33 | 2025 | 1455 | 1.020 |
Why?
|
| Liver Diseases | 2 | 2023 | 34 | 1.020 |
Why?
|
| Aged, 80 and over | 22 | 2025 | 2853 | 1.010 |
Why?
|
| Epithelial Cells | 15 | 2025 | 434 | 1.000 |
Why?
|
| Neoplasms | 3 | 2022 | 1377 | 1.000 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2015 | 257 | 0.990 |
Why?
|
| DNA Mismatch Repair | 2 | 2021 | 28 | 0.960 |
Why?
|
| DNA-Binding Proteins | 6 | 2025 | 561 | 0.910 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2025 | 223 | 0.910 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 186 | 0.900 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2024 | 187 | 0.890 |
Why?
|
| Hospitalization | 3 | 2023 | 485 | 0.880 |
Why?
|
| Lymphatic Metastasis | 5 | 2021 | 81 | 0.880 |
Why?
|
| Dextran Sulfate | 2 | 2021 | 19 | 0.870 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 863 | 0.860 |
Why?
|
| Gene Expression Profiling | 8 | 2024 | 704 | 0.850 |
Why?
|
| Health Status Disparities | 3 | 2020 | 719 | 0.840 |
Why?
|
| beta Catenin | 3 | 2025 | 78 | 0.840 |
Why?
|
| Ferritins | 2 | 2022 | 63 | 0.840 |
Why?
|
| Peptide Hormones | 7 | 2020 | 19 | 0.840 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2019 | 24 | 0.830 |
Why?
|
| Nuclear Proteins | 9 | 2023 | 333 | 0.830 |
Why?
|
| Crohn Disease | 2 | 2024 | 71 | 0.820 |
Why?
|
| Incidence | 9 | 2025 | 1078 | 0.820 |
Why?
|
| Colon | 4 | 2021 | 120 | 0.810 |
Why?
|
| Nutrigenomics | 1 | 2023 | 2 | 0.810 |
Why?
|
| Life Style | 3 | 2017 | 334 | 0.810 |
Why?
|
| Age Factors | 9 | 2025 | 1154 | 0.800 |
Why?
|
| Biological Products | 2 | 2023 | 91 | 0.800 |
Why?
|
| Chromosome Aberrations | 2 | 2014 | 61 | 0.770 |
Why?
|
| Prognosis | 8 | 2024 | 861 | 0.740 |
Why?
|
| Mice | 30 | 2025 | 6644 | 0.730 |
Why?
|
| Cell Movement | 15 | 2025 | 655 | 0.730 |
Why?
|
| District of Columbia | 8 | 2021 | 80 | 0.720 |
Why?
|
| Stomach | 6 | 2020 | 50 | 0.720 |
Why?
|
| RNA, Small Interfering | 5 | 2023 | 436 | 0.720 |
Why?
|
| Hospital Mortality | 1 | 2023 | 210 | 0.720 |
Why?
|
| Dietary Supplements | 1 | 2023 | 213 | 0.700 |
Why?
|
| Risk Assessment | 6 | 2021 | 863 | 0.700 |
Why?
|
| Animals | 41 | 2025 | 16992 | 0.690 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 13 | 0.690 |
Why?
|
| Neoplasm Proteins | 9 | 2019 | 228 | 0.680 |
Why?
|
| Enzymes | 1 | 2021 | 35 | 0.680 |
Why?
|
| Case-Control Studies | 13 | 2022 | 1285 | 0.680 |
Why?
|
| Lymph Nodes | 1 | 2021 | 74 | 0.670 |
Why?
|
| Mitochondria | 4 | 2025 | 523 | 0.670 |
Why?
|
| Cisplatin | 3 | 2025 | 98 | 0.670 |
Why?
|
| Condylomata Acuminata | 1 | 2020 | 6 | 0.670 |
Why?
|
| Urban Health | 3 | 2015 | 101 | 0.660 |
Why?
|
| Cyclooxygenase 2 | 4 | 2013 | 107 | 0.660 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 37 | 0.660 |
Why?
|
| United States | 19 | 2025 | 5205 | 0.650 |
Why?
|
| Homeodomain Proteins | 5 | 2025 | 150 | 0.650 |
Why?
|
| Antineoplastic Agents | 9 | 2025 | 1019 | 0.640 |
Why?
|
| Microsatellite Repeats | 3 | 2024 | 61 | 0.640 |
Why?
|
| Anus Neoplasms | 1 | 2020 | 44 | 0.640 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 167 | 0.630 |
Why?
|
| Uterine Diseases | 1 | 2019 | 5 | 0.630 |
Why?
|
| Polyps | 1 | 2019 | 9 | 0.630 |
Why?
|
| Carotenoids | 2 | 2020 | 74 | 0.620 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 70 | 0.610 |
Why?
|
| Drug Monitoring | 1 | 2020 | 69 | 0.610 |
Why?
|
| Spices | 1 | 2019 | 9 | 0.600 |
Why?
|
| Odds Ratio | 6 | 2020 | 587 | 0.600 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2020 | 9 | 0.600 |
Why?
|
| Epigenesis, Genetic | 6 | 2025 | 291 | 0.600 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 187 | 0.600 |
Why?
|
| Adaptor Proteins, Signal Transducing | 6 | 2018 | 213 | 0.600 |
Why?
|
| Logistic Models | 7 | 2020 | 1009 | 0.590 |
Why?
|
| Sequence Analysis, DNA | 4 | 2019 | 515 | 0.590 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 163 | 0.580 |
Why?
|
| Bacterial Proteins | 12 | 2019 | 595 | 0.560 |
Why?
|
| Histones | 4 | 2017 | 197 | 0.560 |
Why?
|
| Antiviral Agents | 1 | 2020 | 195 | 0.550 |
Why?
|
| Comorbidity | 4 | 2023 | 737 | 0.550 |
Why?
|
| Down-Regulation | 8 | 2021 | 456 | 0.550 |
Why?
|
| Diabetes Mellitus | 3 | 2021 | 539 | 0.540 |
Why?
|
| Liver | 1 | 2021 | 511 | 0.540 |
Why?
|
| Digestive System Neoplasms | 1 | 2017 | 4 | 0.540 |
Why?
|
| Repressor Proteins | 4 | 2021 | 273 | 0.530 |
Why?
|
| Cohort Studies | 10 | 2025 | 1759 | 0.520 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 224 | 0.520 |
Why?
|
| Prospective Studies | 9 | 2025 | 1600 | 0.520 |
Why?
|
| Hepacivirus | 1 | 2017 | 74 | 0.510 |
Why?
|
| Feces | 2 | 2016 | 132 | 0.510 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2019 | 100 | 0.510 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 67 | 0.500 |
Why?
|
| Iran | 7 | 2017 | 202 | 0.500 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2013 | 61 | 0.490 |
Why?
|
| Fatty Liver | 1 | 2017 | 77 | 0.490 |
Why?
|
| DNA Helicases | 2 | 2013 | 48 | 0.490 |
Why?
|
| Pancreatic Cyst | 1 | 2016 | 7 | 0.490 |
Why?
|
| Pathology, Clinical | 1 | 2015 | 4 | 0.480 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2025 | 46 | 0.480 |
Why?
|
| Sex Factors | 6 | 2025 | 1028 | 0.480 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 25 | 0.480 |
Why?
|
| Hospitals, University | 1 | 2015 | 39 | 0.470 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 376 | 0.470 |
Why?
|
| Diverticulosis, Colonic | 1 | 2015 | 3 | 0.470 |
Why?
|
| Minority Groups | 2 | 2023 | 690 | 0.460 |
Why?
|
| Receptor, EphA6 | 1 | 2015 | 2 | 0.460 |
Why?
|
| Tumor Cells, Cultured | 10 | 2020 | 508 | 0.450 |
Why?
|
| Genome, Human | 2 | 2014 | 144 | 0.450 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 760 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 223 | 0.450 |
Why?
|
| CpG Islands | 4 | 2018 | 109 | 0.450 |
Why?
|
| Haplotypes | 3 | 2017 | 197 | 0.440 |
Why?
|
| Immunohistochemistry | 10 | 2018 | 934 | 0.430 |
Why?
|
| Body Mass Index | 2 | 2020 | 925 | 0.430 |
Why?
|
| Chi-Square Distribution | 6 | 2015 | 236 | 0.430 |
Why?
|
| Genetic Variation | 1 | 2017 | 430 | 0.420 |
Why?
|
| Nerve Tissue Proteins | 2 | 2013 | 386 | 0.420 |
Why?
|
| Obesity | 3 | 2021 | 1151 | 0.420 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 122 | 0.420 |
Why?
|
| Proteins | 3 | 2013 | 382 | 0.410 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2019 | 165 | 0.410 |
Why?
|
| MutS Homolog 2 Protein | 4 | 2024 | 32 | 0.410 |
Why?
|
| Genetic Markers | 2 | 2014 | 150 | 0.410 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2022 | 220 | 0.400 |
Why?
|
| Gene Amplification | 2 | 2012 | 23 | 0.400 |
Why?
|
| ras Proteins | 2 | 2014 | 54 | 0.400 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 638 | 0.390 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2025 | 307 | 0.380 |
Why?
|
| Chromosomes, Human, X | 1 | 2012 | 23 | 0.380 |
Why?
|
| Gastrointestinal Tract | 2 | 2023 | 71 | 0.380 |
Why?
|
| Gastroesophageal Reflux | 1 | 2012 | 37 | 0.370 |
Why?
|
| Receptors, Calcitriol | 2 | 2019 | 69 | 0.370 |
Why?
|
| Cytokines | 3 | 2024 | 678 | 0.370 |
Why?
|
| HCT116 Cells | 4 | 2021 | 40 | 0.370 |
Why?
|
| Linkage Disequilibrium | 1 | 2012 | 86 | 0.360 |
Why?
|
| Proteomics | 6 | 2021 | 378 | 0.360 |
Why?
|
| Diverticulum, Colon | 2 | 2022 | 3 | 0.360 |
Why?
|
| Phylogeny | 4 | 2021 | 769 | 0.360 |
Why?
|
| Disease Progression | 8 | 2025 | 667 | 0.350 |
Why?
|
| Diarrhea | 2 | 2022 | 95 | 0.350 |
Why?
|
| Overweight | 1 | 2014 | 249 | 0.350 |
Why?
|
| Butyrates | 1 | 2011 | 34 | 0.340 |
Why?
|
| Cation Transport Proteins | 1 | 2011 | 35 | 0.340 |
Why?
|
| Neoplasm Invasiveness | 8 | 2021 | 290 | 0.340 |
Why?
|
| Trans-Activators | 4 | 2024 | 192 | 0.340 |
Why?
|
| Genes, APC | 2 | 2009 | 15 | 0.340 |
Why?
|
| Oxidative Stress | 3 | 2024 | 1003 | 0.330 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 1869 | 0.330 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2019 | 56 | 0.330 |
Why?
|
| Carrier Proteins | 5 | 2019 | 321 | 0.320 |
Why?
|
| Young Adult | 7 | 2025 | 5080 | 0.320 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2017 | 734 | 0.320 |
Why?
|
| Genomic Instability | 2 | 2025 | 37 | 0.320 |
Why?
|
| Chromosomal Instability | 2 | 2010 | 20 | 0.320 |
Why?
|
| Esophageal Neoplasms | 1 | 2011 | 140 | 0.310 |
Why?
|
| Vitamin D | 1 | 2011 | 196 | 0.310 |
Why?
|
| Cell Survival | 9 | 2025 | 945 | 0.300 |
Why?
|
| Carcinoma in Situ | 1 | 2009 | 16 | 0.300 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2013 | 310 | 0.300 |
Why?
|
| Autophagy | 3 | 2022 | 140 | 0.300 |
Why?
|
| Databases, Genetic | 2 | 2021 | 103 | 0.300 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2008 | 7 | 0.300 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2021 | 91 | 0.290 |
Why?
|
| Mice, Nude | 7 | 2025 | 408 | 0.290 |
Why?
|
| Gene Silencing | 3 | 2021 | 154 | 0.290 |
Why?
|
| Signal Transduction | 9 | 2025 | 2157 | 0.290 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 1596 | 0.280 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 61 | 0.280 |
Why?
|
| Mice, Inbred BALB C | 8 | 2025 | 694 | 0.280 |
Why?
|
| Peptide Library | 2 | 2018 | 28 | 0.270 |
Why?
|
| Lysosomes | 2 | 2019 | 86 | 0.270 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 440 | 0.270 |
Why?
|
| Tissue Array Analysis | 4 | 2018 | 80 | 0.270 |
Why?
|
| Neoplastic Stem Cells | 3 | 2024 | 99 | 0.270 |
Why?
|
| Inflammation | 4 | 2022 | 758 | 0.270 |
Why?
|
| Azacitidine | 2 | 2020 | 21 | 0.270 |
Why?
|
| Body Weight | 2 | 2021 | 429 | 0.270 |
Why?
|
| Transcription Factor AP-1 | 1 | 2007 | 34 | 0.260 |
Why?
|
| Tetrahydrofolates | 1 | 2007 | 1 | 0.260 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2025 | 347 | 0.260 |
Why?
|
| Folic Acid | 1 | 2007 | 49 | 0.260 |
Why?
|
| Survival Rate | 3 | 2020 | 355 | 0.260 |
Why?
|
| Aspirin | 2 | 2022 | 89 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2005 | 152 | 0.250 |
Why?
|
| Cell Line | 11 | 2021 | 1410 | 0.250 |
Why?
|
| Mass Screening | 3 | 2019 | 541 | 0.250 |
Why?
|
| Stress, Psychological | 1 | 2013 | 661 | 0.250 |
Why?
|
| Time Factors | 4 | 2017 | 1857 | 0.250 |
Why?
|
| Computational Biology | 4 | 2021 | 327 | 0.250 |
Why?
|
| Intestinal Mucosa | 2 | 2021 | 134 | 0.250 |
Why?
|
| Genotype | 4 | 2020 | 800 | 0.240 |
Why?
|
| Blotting, Western | 8 | 2012 | 883 | 0.240 |
Why?
|
| Follow-Up Studies | 2 | 2023 | 1067 | 0.240 |
Why?
|
| Hepatectomy | 1 | 2025 | 8 | 0.240 |
Why?
|
| Semaphorins | 1 | 2025 | 4 | 0.240 |
Why?
|
| Colectomy | 1 | 2025 | 24 | 0.230 |
Why?
|
| Olfaction Disorders | 1 | 2025 | 12 | 0.230 |
Why?
|
| Patient Compliance | 2 | 2019 | 233 | 0.230 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2025 | 33 | 0.230 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2025 | 11 | 0.230 |
Why?
|
| Biopsy | 3 | 2019 | 177 | 0.230 |
Why?
|
| Delayed Diagnosis | 1 | 2025 | 38 | 0.230 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2025 | 34 | 0.230 |
Why?
|
| Early Detection of Cancer | 3 | 2020 | 449 | 0.230 |
Why?
|
| Fluorouracil | 1 | 2005 | 47 | 0.230 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2025 | 8 | 0.220 |
Why?
|
| I-kappa B Kinase | 1 | 2025 | 51 | 0.220 |
Why?
|
| Catechin | 1 | 2025 | 39 | 0.220 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2025 | 95 | 0.220 |
Why?
|
| Stomach Ulcer | 1 | 2004 | 8 | 0.220 |
Why?
|
| Gastritis | 1 | 2004 | 13 | 0.220 |
Why?
|
| Phenotype | 3 | 2023 | 780 | 0.220 |
Why?
|
| NFI Transcription Factors | 1 | 2024 | 2 | 0.220 |
Why?
|
| Patient Participation | 1 | 2026 | 94 | 0.220 |
Why?
|
| Glutathione | 1 | 2025 | 171 | 0.220 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2023 | 31 | 0.220 |
Why?
|
| Age of Onset | 1 | 2024 | 114 | 0.220 |
Why?
|
| RNA, Messenger | 7 | 2024 | 1271 | 0.220 |
Why?
|
| Aging | 2 | 2025 | 783 | 0.220 |
Why?
|
| DNA, Viral | 2 | 2020 | 311 | 0.210 |
Why?
|
| Translocation, Genetic | 1 | 2004 | 40 | 0.210 |
Why?
|
| Administration, Oral | 2 | 2023 | 260 | 0.210 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2024 | 5 | 0.210 |
Why?
|
| Alleles | 2 | 2020 | 352 | 0.210 |
Why?
|
| Gene Dosage | 2 | 2014 | 75 | 0.210 |
Why?
|
| Vomiting | 1 | 2023 | 14 | 0.210 |
Why?
|
| Demography | 2 | 2016 | 195 | 0.210 |
Why?
|
| Oxygen | 1 | 2025 | 218 | 0.210 |
Why?
|
| Phytotherapy | 1 | 2024 | 75 | 0.210 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2024 | 20 | 0.210 |
Why?
|
| Mitosis | 1 | 2025 | 114 | 0.210 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2019 | 161 | 0.210 |
Why?
|
| Adenosine | 1 | 2024 | 62 | 0.200 |
Why?
|
| Ceramides | 1 | 2024 | 44 | 0.200 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2003 | 11 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 220 | 0.200 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2014 | 15 | 0.200 |
Why?
|
| Virulence | 1 | 2024 | 246 | 0.200 |
Why?
|
| NF-kappa B | 5 | 2025 | 358 | 0.200 |
Why?
|
| Viral Load | 2 | 2025 | 348 | 0.190 |
Why?
|
| Diet | 2 | 2023 | 826 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2022 | 146 | 0.190 |
Why?
|
| Histone Code | 1 | 2022 | 13 | 0.190 |
Why?
|
| Troponin | 1 | 2022 | 17 | 0.190 |
Why?
|
| Sirtuin 1 | 1 | 2022 | 34 | 0.190 |
Why?
|
| Histone Deacetylase 1 | 2 | 2020 | 16 | 0.180 |
Why?
|
| Community-Based Participatory Research | 1 | 2026 | 352 | 0.180 |
Why?
|
| Retroelements | 1 | 2021 | 14 | 0.180 |
Why?
|
| Caspases | 1 | 2002 | 148 | 0.180 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2021 | 3 | 0.180 |
Why?
|
| Naphthalimides | 1 | 2021 | 3 | 0.180 |
Why?
|
| Analysis of Variance | 2 | 2014 | 575 | 0.180 |
Why?
|
| Acetylation | 4 | 2020 | 107 | 0.180 |
Why?
|
| STAT3 Transcription Factor | 2 | 2019 | 102 | 0.180 |
Why?
|
| Microarray Analysis | 2 | 2014 | 64 | 0.180 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2020 | 45 | 0.170 |
Why?
|
| Benzimidazoles | 1 | 2021 | 43 | 0.170 |
Why?
|
| Reactive Oxygen Species | 5 | 2025 | 532 | 0.170 |
Why?
|
| Transfection | 5 | 2019 | 532 | 0.170 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2020 | 11 | 0.170 |
Why?
|
| Zebrafish | 1 | 2022 | 146 | 0.170 |
Why?
|
| Exosomes | 2 | 2020 | 126 | 0.170 |
Why?
|
| Forkhead Transcription Factors | 1 | 2021 | 78 | 0.170 |
Why?
|
| Adolescent | 6 | 2025 | 6081 | 0.170 |
Why?
|
| Latin America | 1 | 2020 | 55 | 0.170 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2020 | 13 | 0.170 |
Why?
|
| Mesalamine | 1 | 2020 | 2 | 0.170 |
Why?
|
| Diverticulitis | 1 | 2020 | 2 | 0.170 |
Why?
|
| Occult Blood | 1 | 2020 | 32 | 0.170 |
Why?
|
| Antioxidants | 1 | 2024 | 443 | 0.170 |
Why?
|
| Serotonin | 1 | 2021 | 123 | 0.170 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2020 | 66 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 94 | 0.160 |
Why?
|
| Anal Canal | 1 | 2020 | 32 | 0.160 |
Why?
|
| Hedgehog Proteins | 1 | 2021 | 54 | 0.160 |
Why?
|
| Liver Function Tests | 1 | 2020 | 19 | 0.160 |
Why?
|
| rho-Associated Kinases | 2 | 2025 | 36 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 25 | 0.160 |
Why?
|
| DNA Damage | 2 | 2020 | 356 | 0.160 |
Why?
|
| Interferons | 1 | 2020 | 40 | 0.160 |
Why?
|
| Mexico | 1 | 2021 | 298 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 179 | 0.160 |
Why?
|
| Interleukins | 1 | 2020 | 40 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 63 | 0.160 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2019 | 10 | 0.160 |
Why?
|
| Up-Regulation | 4 | 2019 | 536 | 0.160 |
Why?
|
| Cannabidiol | 1 | 2019 | 10 | 0.160 |
Why?
|
| DNA, Neoplasm | 1 | 2020 | 92 | 0.160 |
Why?
|
| Iridoids | 1 | 2019 | 5 | 0.150 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2019 | 5 | 0.150 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 13 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2020 | 161 | 0.150 |
Why?
|
| DNA | 1 | 2022 | 592 | 0.150 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 3156 | 0.150 |
Why?
|
| Gastritis, Atrophic | 1 | 2019 | 13 | 0.150 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2019 | 12 | 0.150 |
Why?
|
| Cholecalciferol | 1 | 2019 | 20 | 0.150 |
Why?
|
| Mitochondrial Proteins | 1 | 2019 | 118 | 0.140 |
Why?
|
| Oman | 2 | 2008 | 7 | 0.140 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 238 | 0.140 |
Why?
|
| Enzyme Inhibitors | 2 | 2019 | 458 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2019 | 259 | 0.140 |
Why?
|
| STAT Transcription Factors | 1 | 2017 | 13 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 611 | 0.140 |
Why?
|
| Janus Kinases | 1 | 2017 | 23 | 0.140 |
Why?
|
| Smoking | 2 | 2019 | 1024 | 0.130 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 74 | 0.130 |
Why?
|
| Cytoskeletal Proteins | 1 | 2018 | 116 | 0.130 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 719 | 0.130 |
Why?
|
| Sex Distribution | 1 | 2017 | 224 | 0.130 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2016 | 11 | 0.130 |
Why?
|
| Hydrazines | 1 | 2016 | 22 | 0.130 |
Why?
|
| Colonoscopes | 1 | 2016 | 2 | 0.130 |
Why?
|
| Treatment Outcome | 1 | 2021 | 1604 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 75 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2017 | 269 | 0.120 |
Why?
|
| Hyperplasia | 1 | 2016 | 39 | 0.120 |
Why?
|
| Phosphoproteins | 1 | 2018 | 206 | 0.120 |
Why?
|
| Peptide Fragments | 1 | 2018 | 307 | 0.120 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 113 | 0.120 |
Why?
|
| SEER Program | 1 | 2016 | 164 | 0.120 |
Why?
|
| DNA, Fungal | 3 | 1992 | 49 | 0.120 |
Why?
|
| Rectum | 2 | 2019 | 27 | 0.110 |
Why?
|
| Cell Hypoxia | 2 | 2025 | 60 | 0.110 |
Why?
|
| Gastrins | 1 | 2015 | 9 | 0.110 |
Why?
|
| Curcumin | 1 | 2016 | 118 | 0.110 |
Why?
|
| Mucins | 2 | 2008 | 73 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 432 | 0.110 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 609 | 0.110 |
Why?
|
| Immunoblotting | 2 | 2008 | 181 | 0.110 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2005 | 76 | 0.110 |
Why?
|
| Endoscopy | 1 | 2014 | 17 | 0.110 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2014 | 3 | 0.110 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2014 | 2 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 37 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2005 | 32 | 0.110 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2014 | 23 | 0.110 |
Why?
|
| Cell Cycle Proteins | 3 | 2023 | 241 | 0.110 |
Why?
|
| Appointments and Schedules | 1 | 2014 | 32 | 0.110 |
Why?
|
| Hypertension | 1 | 2021 | 835 | 0.110 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2014 | 5 | 0.110 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 1092 | 0.110 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2014 | 7 | 0.110 |
Why?
|
| RNA, Untranslated | 1 | 2014 | 50 | 0.100 |
Why?
|
| Metagenomics | 1 | 2013 | 46 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 3 | 2021 | 196 | 0.100 |
Why?
|
| Hydroxamic Acids | 1 | 2013 | 33 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 173 | 0.100 |
Why?
|
| Cell Cycle | 4 | 2015 | 346 | 0.100 |
Why?
|
| Cell Division | 3 | 2010 | 311 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 118 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 249 | 0.100 |
Why?
|
| Hospitals, General | 1 | 2012 | 5 | 0.100 |
Why?
|
| Deoxyribonucleases | 1 | 2013 | 27 | 0.100 |
Why?
|
| Gastroscopy | 1 | 2012 | 9 | 0.100 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2010 | 70 | 0.100 |
Why?
|
| Homeostasis | 1 | 2014 | 192 | 0.100 |
Why?
|
| Endothelin-2 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Endothelin-3 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Phycomyces | 1 | 1992 | 1 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2012 | 5 | 0.100 |
Why?
|
| Molecular Imaging | 1 | 2012 | 30 | 0.100 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 14 | 0.100 |
Why?
|
| Gene Expression | 2 | 2018 | 701 | 0.090 |
Why?
|
| Amino Acids | 1 | 2013 | 148 | 0.090 |
Why?
|
| PPAR gamma | 1 | 2012 | 55 | 0.090 |
Why?
|
| Paneth Cells | 1 | 2012 | 3 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 1070 | 0.090 |
Why?
|
| Ribonucleoproteins | 1 | 2012 | 31 | 0.090 |
Why?
|
| Quercetin | 1 | 2012 | 46 | 0.090 |
Why?
|
| Unfolded Protein Response | 1 | 2012 | 22 | 0.090 |
Why?
|
| Catalase | 2 | 2024 | 110 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2024 | 108 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2005 | 234 | 0.090 |
Why?
|
| Metaplasia | 2 | 2023 | 39 | 0.090 |
Why?
|
| Introns | 1 | 2012 | 79 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1063 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 3 | 2019 | 189 | 0.090 |
Why?
|
| Exons | 1 | 2012 | 92 | 0.090 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 82 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 154 | 0.090 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2011 | 12 | 0.090 |
Why?
|
| Dictyostelium | 2 | 1989 | 45 | 0.090 |
Why?
|
| Gene Frequency | 1 | 2012 | 206 | 0.090 |
Why?
|
| Glutamate Plasma Membrane Transport Proteins | 1 | 2011 | 2 | 0.090 |
Why?
|
| Gene Fusion | 1 | 2011 | 7 | 0.090 |
Why?
|
| Length of Stay | 1 | 2012 | 229 | 0.090 |
Why?
|
| Mortality | 1 | 2012 | 175 | 0.090 |
Why?
|
| Seasons | 1 | 2011 | 139 | 0.080 |
Why?
|
| Complement C9 | 1 | 2010 | 2 | 0.080 |
Why?
|
| Cathepsins | 1 | 2010 | 9 | 0.080 |
Why?
|
| Protein Binding | 3 | 2025 | 1082 | 0.080 |
Why?
|
| Longevity | 1 | 2012 | 173 | 0.080 |
Why?
|
| Alpha-Globulins | 1 | 2010 | 4 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2021 | 986 | 0.080 |
Why?
|
| Genes, myc | 1 | 2010 | 31 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 237 | 0.080 |
Why?
|
| Oncogenes | 2 | 2020 | 44 | 0.080 |
Why?
|
| Cell Membrane | 2 | 2012 | 403 | 0.080 |
Why?
|
| Motor Activity | 1 | 2013 | 437 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2013 | 363 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2012 | 561 | 0.080 |
Why?
|
| Puerto Rico | 2 | 2025 | 1413 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2018 | 196 | 0.080 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2010 | 13 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 296 | 0.080 |
Why?
|
| Drug Synergism | 2 | 2025 | 195 | 0.080 |
Why?
|
| Chromosomes, Human | 1 | 2010 | 37 | 0.080 |
Why?
|
| Dependovirus | 1 | 1989 | 18 | 0.080 |
Why?
|
| Host-Pathogen Interactions | 2 | 2024 | 209 | 0.080 |
Why?
|
| DNA Primers | 2 | 2010 | 294 | 0.080 |
Why?
|
| Genes, p16 | 1 | 2009 | 11 | 0.070 |
Why?
|
| Sex Characteristics | 1 | 2011 | 258 | 0.070 |
Why?
|
| Nuclear Envelope | 1 | 2008 | 10 | 0.070 |
Why?
|
| Proteome | 1 | 2010 | 152 | 0.070 |
Why?
|
| Cell Fractionation | 1 | 2008 | 29 | 0.070 |
Why?
|
| Cell Death | 2 | 2020 | 278 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2020 | 368 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2008 | 154 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2020 | 200 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2013 | 79 | 0.070 |
Why?
|
| Genetics, Population | 1 | 2008 | 121 | 0.070 |
Why?
|
| Isotope Labeling | 3 | 2013 | 26 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2023 | 384 | 0.070 |
Why?
|
| Outpatients | 2 | 2019 | 37 | 0.070 |
Why?
|
| Plasmids | 1 | 1988 | 244 | 0.070 |
Why?
|
| Homocysteine | 1 | 2007 | 21 | 0.070 |
Why?
|
| Vitamin B 12 | 1 | 2007 | 23 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 458 | 0.060 |
Why?
|
| Vitamins | 1 | 2007 | 81 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 152 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 1988 | 383 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2025 | 17 | 0.060 |
Why?
|
| Peptic Ulcer | 1 | 2005 | 15 | 0.060 |
Why?
|
| Smell | 1 | 2025 | 40 | 0.060 |
Why?
|
| Independent Living | 1 | 2025 | 47 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 652 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2025 | 83 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2025 | 127 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2018 | 1035 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2021 | 241 | 0.050 |
Why?
|
| Base Sequence | 3 | 2012 | 983 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2025 | 88 | 0.050 |
Why?
|
| Propensity Score | 1 | 2024 | 59 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 455 | 0.050 |
Why?
|
| Histocompatibility Antigens | 1 | 2023 | 12 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2024 | 36 | 0.050 |
Why?
|
| Gastric Mucins | 1 | 2023 | 3 | 0.050 |
Why?
|
| Virus Activation | 1 | 2024 | 38 | 0.050 |
Why?
|
| Nucleosomes | 2 | 2017 | 30 | 0.050 |
Why?
|
| Cobalt | 2 | 2016 | 29 | 0.050 |
Why?
|
| Community-Institutional Relations | 1 | 2026 | 219 | 0.050 |
Why?
|
| ROC Curve | 2 | 2016 | 159 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 61 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 306 | 0.050 |
Why?
|
| RNA, Neoplasm | 2 | 2014 | 25 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2022 | 7 | 0.050 |
Why?
|
| HIV Infections | 1 | 2017 | 2586 | 0.050 |
Why?
|
| Peptide Termination Factors | 1 | 2022 | 3 | 0.050 |
Why?
|
| Wnt Proteins | 1 | 2022 | 23 | 0.050 |
Why?
|
| Prostate | 1 | 2023 | 155 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 100 | 0.050 |
Why?
|
| Haplorhini | 1 | 2002 | 23 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2002 | 30 | 0.050 |
Why?
|
| Caspase 8 | 1 | 2002 | 32 | 0.050 |
Why?
|
| Vimentin | 1 | 2022 | 44 | 0.050 |
Why?
|
| Calcium Signaling | 1 | 2003 | 107 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1124 | 0.050 |
Why?
|
| Rats | 3 | 2017 | 3735 | 0.050 |
Why?
|
| Embryonic Development | 1 | 2022 | 83 | 0.040 |
Why?
|
| CDC2 Protein Kinase | 1 | 2021 | 19 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2021 | 32 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2002 | 227 | 0.040 |
Why?
|
| Genomics | 1 | 2023 | 293 | 0.040 |
Why?
|
| Helicobacter felis | 1 | 2021 | 2 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2002 | 462 | 0.040 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 41 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2000 | 411 | 0.040 |
Why?
|
| Propidium | 1 | 2000 | 20 | 0.040 |
Why?
|
| Cyclin E | 1 | 2000 | 14 | 0.040 |
Why?
|
| Cyclins | 1 | 2000 | 34 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2021 | 416 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2001 | 168 | 0.040 |
Why?
|
| Mass Spectrometry | 2 | 2013 | 280 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2000 | 55 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 56 | 0.040 |
Why?
|
| Pinocytosis | 1 | 2020 | 10 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 158 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2021 | 182 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 152 | 0.040 |
Why?
|
| Glutathione Peroxidase | 1 | 2000 | 112 | 0.040 |
Why?
|
| Calcium | 2 | 2019 | 491 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2003 | 1621 | 0.040 |
Why?
|
| Integrins | 1 | 2020 | 54 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2000 | 158 | 0.040 |
Why?
|
| Quality of Life | 1 | 2025 | 616 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 53 | 0.040 |
Why?
|
| Cathartics | 1 | 2019 | 6 | 0.040 |
Why?
|
| Probiotics | 1 | 2020 | 37 | 0.040 |
Why?
|
| Genes, ras | 1 | 2019 | 24 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2003 | 638 | 0.040 |
Why?
|
| Colon, Ascending | 1 | 2019 | 3 | 0.040 |
Why?
|
| Colon, Sigmoid | 1 | 2019 | 4 | 0.040 |
Why?
|
| Colon, Transverse | 1 | 2019 | 5 | 0.040 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 36 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 51 | 0.040 |
Why?
|
| Gene Targeting | 1 | 2019 | 39 | 0.040 |
Why?
|
| Culture Media | 1 | 1999 | 96 | 0.040 |
Why?
|
| Acetylglucosaminidase | 1 | 2019 | 2 | 0.040 |
Why?
|
| Cathelicidins | 1 | 2019 | 4 | 0.040 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2019 | 90 | 0.040 |
Why?
|
| Gastrectomy | 1 | 2019 | 13 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1999 | 64 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 215 | 0.040 |
Why?
|
| Acid Phosphatase | 1 | 2019 | 23 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2021 | 1180 | 0.040 |
Why?
|
| Transient Receptor Potential Channels | 1 | 2019 | 8 | 0.040 |
Why?
|
| Cell Count | 1 | 1999 | 145 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 108 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2019 | 81 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 129 | 0.040 |
Why?
|
| Cytidine Deaminase | 1 | 2018 | 36 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2018 | 57 | 0.040 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2019 | 38 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 95 | 0.040 |
Why?
|
| Receptor, IGF Type 2 | 1 | 2018 | 7 | 0.040 |
Why?
|
| Clathrin | 1 | 2018 | 21 | 0.040 |
Why?
|
| Models, Biological | 1 | 2021 | 712 | 0.030 |
Why?
|
| Azepines | 1 | 2018 | 22 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 173 | 0.030 |
Why?
|
| Microbial Viability | 1 | 2018 | 42 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 2018 | 21 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 2018 | 36 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 32 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 310 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 115 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 135 | 0.030 |
Why?
|
| Triazoles | 1 | 2018 | 102 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2017 | 8 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 139 | 0.030 |
Why?
|
| Colombia | 1 | 2017 | 31 | 0.030 |
Why?
|
| Protein Transport | 1 | 2018 | 296 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1175 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 161 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2018 | 388 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2017 | 127 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 506 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2016 | 95 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 1081 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 95 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2017 | 104 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 184 | 0.030 |
Why?
|
| Solubility | 1 | 2016 | 139 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 671 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2017 | 188 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2016 | 190 | 0.030 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 2015 | 8 | 0.030 |
Why?
|
| Receptors, Growth Factor | 1 | 2015 | 11 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2018 | 460 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2018 | 876 | 0.030 |
Why?
|
| Nod1 Signaling Adaptor Protein | 1 | 2014 | 1 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 43 | 0.030 |
Why?
|
| I-kappa B Proteins | 1 | 2014 | 36 | 0.030 |
Why?
|
| Peptides | 1 | 2018 | 372 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 68 | 0.030 |
Why?
|
| Hospitals | 1 | 2014 | 117 | 0.030 |
Why?
|
| Proprotein Convertases | 1 | 2013 | 8 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2013 | 87 | 0.030 |
Why?
|
| Mannose-Binding Lectins | 1 | 2013 | 14 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2013 | 48 | 0.020 |
Why?
|
| Protestantism | 1 | 2012 | 5 | 0.020 |
Why?
|
| Isoelectric Focusing | 1 | 2012 | 13 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2013 | 197 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 162 | 0.020 |
Why?
|
| 1-Propanol | 1 | 1992 | 2 | 0.020 |
Why?
|
| Chloroform | 1 | 1992 | 4 | 0.020 |
Why?
|
| Anilides | 1 | 2012 | 28 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 1992 | 9 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1992 | 29 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 100 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2012 | 60 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2012 | 64 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2017 | 1766 | 0.020 |
Why?
|
| Positive Transcriptional Elongation Factor B | 1 | 2012 | 15 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1992 | 86 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 58 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 465 | 0.020 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2011 | 33 | 0.020 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2010 | 11 | 0.020 |
Why?
|
| Densitometry | 1 | 2010 | 16 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 114 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2010 | 42 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2010 | 47 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 98 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1234 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2010 | 258 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 1989 | 20 | 0.020 |
Why?
|
| Carcinogens | 1 | 2010 | 126 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2010 | 77 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 1989 | 27 | 0.020 |
Why?
|
| Imidazoles | 1 | 2010 | 142 | 0.020 |
Why?
|
| KB Cells | 1 | 1989 | 7 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1989 | 36 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 201 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 1989 | 154 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1988 | 165 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1989 | 1542 | 0.020 |
Why?
|
| Phospholipases A | 1 | 2003 | 9 | 0.010 |
Why?
|
| Phospholipases A2 | 1 | 2003 | 9 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 2003 | 23 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 2003 | 49 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 2003 | 91 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 2003 | 59 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2001 | 166 | 0.010 |
Why?
|
| Ranitidine | 1 | 1999 | 4 | 0.010 |
Why?
|
| Histamine H2 Antagonists | 1 | 1999 | 5 | 0.010 |
Why?
|
| Clarithromycin | 1 | 1999 | 9 | 0.010 |
Why?
|
| Bismuth | 1 | 1999 | 6 | 0.010 |
Why?
|
| Metronidazole | 1 | 1999 | 16 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1999 | 153 | 0.010 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1992 | 25 | 0.010 |
Why?
|
| Multigene Family | 1 | 1992 | 105 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1992 | 210 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1992 | 136 | 0.010 |
Why?
|
| Extrachromosomal Inheritance | 1 | 1989 | 2 | 0.000 |
Why?
|
| Electrophoresis | 1 | 1989 | 24 | 0.000 |
Why?
|